UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                  SCHEDULE 13D
                    Under the Securities Exchange Act of 1934
                            (Amendment No. ___1___)*

                           China Pharma Holdings, Inc.
--------------------------------------------------------------------------------
                                (Name of Issuer)


           Common Stock, par value $0.001 per share [GRAPHIC OMITTED]
--------------------------------------------------------------------------------
                         (Title of Class of Securities)


                                    16941T104
--------------------------------------------------------------------------------
                                 (CUSIP Number)


                                    Jian Yang
                         2nd Floor, No. 17, Jinpan Road
                         Haikou, Hainan Province, China
                           Telephone: 86-898-6681 1730
--------------------------------------------------------------------------------
                  (Name, Address and Telephone Number of Person
                Authorized to Receive Notices and Communications)


                                November 6, 2007
--------------------------------------------------------------------------------
             (Date of Event which Requires Filing of this Statement)

If the filing person has previously  filed a statement on Schedule 13G to report
the  acquisition  that is the subject of this  Schedule  13D, and is filing this
schedule because of ss.ss.240.13d-1(e),  240.13d-1(f) or 240.13d-1(g), check the
following box. [ ]

Note:  Schedules  filed in paper format shall include a signed original and five
copies of the  schedule,  including  all exhibits.  See  ss.240.13d-7  for other
parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for  any  subsequent   amendment   containing   information  which  would  alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 ("Act") or otherwise  subject to the liabilities of that section of the Act
but  shall be  subject  to all other  provisions  of the Act  (however,  see the
Notes).



                                                                               1



                               CUSIP No. 16941T104





1.   Names of Reporting  Persons.  I.R.S.  Identification  Nos. of above persons
     (entities only).

     Jian Yang

--------------------------------------------------------------------------------

2.   Check the Appropriate Box if a Member of a Group (See Instructions)
     (a) [ ]
     (b) [ X]

--------------------------------------------------------------------------------

3.   SEC Use Only

--------------------------------------------------------------------------------

4.   Source of Funds (See Instructions)

     OO

--------------------------------------------------------------------------------

5.   Check if Disclosure of Legal Proceedings Is Required Pursuant to
     Items 2(d) or 2(e) [ ]

--------------------------------------------------------------------------------

6.   Citizenship or Place of Organization

     The People's Republic of China

--------------------------------------------------------------------------------

                    7. Sole Voting Power 2,278,815 shares
    Number          ------------------------------------------------------------
   of Shares
 Beneficially       8. Shared Voting Power 0
     Owned
      by            ------------------------------------------------------------
     Each           9. Sole Dispositive Power 2,278,815 shares
   Reporting
  Person With       ------------------------------------------------------------
                    10. Shared Dispositive Power 0

--------------------------------------------------------------------------------

11.  Aggregate  Amount  Beneficially  Owned by Each Reporting  Person

     2,278,815 shares

--------------------------------------------------------------------------------

12.  Check if the  Aggregate  Amount in Row (11)  Excludes  Certain  Shares (See
     Instructions) []

--------------------------------------------------------------------------------

13.  Percent of Class Represented by Amount in Row (11) 6.1%

--------------------------------------------------------------------------------



                                                                               2




14.  Type of Reporting Person (See Instructions) IN


Item 1. Security and Issuer

This  statement  relates to the common  stock,  par value  $0.001  (the  "Common
Stock") of China Pharma Holdings,  Inc., a Delaware corporation (the "Company").
The  Company's  principal  executive  offices are located at 2nd Floor,  No. 17,
Jinpan Road, Haikou, Hainan Province, China. 570216.



Item 2. Identity and Background

     (a)  This statement is filed by Jian Yang ("Reporting Person").

     (b)  The  residence of the  Reporting  Person is Room 5B,  Building 7, Asia
          Luxury Garden, 1 Haoyuan Street, Haikou, Hainan Province, P. R. China.
          570206;

     (c)  The Reporting  Person is the secretary of the Issuer.  She is also the
          executive vice manager Hainan Helpson Medicine and Biotechnology  Co.,
          Ltd, the wholly owned sub-subsidiary of the Issuer.

     (d)  Reporting  Person has not, during the last five years,  been convicted
          in a criminal  proceeding  (excluding  traffic  violations  or similar
          misdemeanors);

     (e)  The Reporting Person has not, during the last five years, been a party
          to a  civil  proceeding  of  a  judicial  or  administrative  body  of
          competent  jurisdiction  as a result of which was or is  subject  to a
          judgment,  decree or final order  enjoining  future  violations of, or
          prohibiting  or  mandating  activities  subject  to,  federal or state
          securities laws or finding any violation with respect to such laws;

     (f)  The Reporting Person is a citizen of the People's Republic of China



Item 3. Source and Amount of Funds or Other Consideration

Tsui  Heung  Mei  ("Tsui")   entered  into  a  Stock  Transfer   Agreement  (the
"Agreement")  with the  Reporting  Person  and the  Issuer  which was  closed on
November 6, 2007. Pursuant to the Agreement,  the Reporting Person acquired from
Tsui 2,278,815 shares of common stock of the Company held by Tsui.



Item 4. Purpose of Transaction

The purpose of the  acquisition of the shares of common stock reported herein by
the Reporting  Person was for  investment.  The Reporting  Person has no present
plans or proposals  relating to or that would result in (a) the  acquisition  by
any  person of  additional  securities  of the  issuer,  or the  disposition  of
securities of the issuer; (b) an extraordinary corporate transaction,  such as a
merger,  reorganization  or  liquidation,  involving  the  issuer  or any of its
subsidiaries;  (c) The  Reporting  Person  has no  present  plans  or  proposals
relating to or that would  result in a sale or transfer of a material  amount of
assets of the issuer or any of its  subsidiaries;  (d) any change in the present
board of directors or management of the Company including any plans or proposals
to change the number of term of directors  or to fill any existing  vacancies on
the board;  (e) any material  change in the present  capitalization  or dividend
policy of the Company;  (f) any other material change in the Company's  business
or  corporate   structure;   (g)  changes  in  the  Company's   Certificate   of
Incorporation  or other actions which may impede the  acquisition  of control of
the Company by any person;  (h) causing a class of  securities of the Company to
be delisted from a national  securities exchange or to cease to be authorized to



                                                                               3


be  quoted  in  an  inter-dealer  quotation  system  of  a  registered  national
securities association; (i) a class of equity securities of the Company becoming
eligible for  termination of  registration  pursuant to Section  12(g)(4) of the
Act; or (j) any action similar to any of those enumerated above.


Item 5. Interest in Securities of the Issuer

     (a)  The Reporting  Person is the beneficial  owner of 2,278,815  shares of
          common  stock of the  Company.  The Company had  37,228,938  shares of
          common  stock  outstanding  as of  November  6,  2007.  Based  on that
          reported number of shares of common stock  outstanding,  The Reporting
          Person has beneficial ownership of approximately 6.1% of the Company's
          outstanding common stock.

     (b)  The Reporting Person has sole power to vote or direct to vote and sole
          power to dispose or to direct the  disposition of 2,278,815  shares of
          common stock.

     (c)  Reference  is  made to  Item  5(a)  above  for  information  regarding
          transactions  in  Company's  common  stock  effected by the  Reporting
          Person during the past 60 days.

     (d)  No other  person  has the right to  receive or the power to direct the
          receipt  of  dividends  from,  or the  proceeds  from the sale of such
          securities.

     (e)  Not applicable.



Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
        Securities of the Issuer

Other than as described  above,  to the best knowledge of the Reporting  Person,
there are no contracts, arrangements,  understandings or relationships (legal or
otherwise)  between  reporting  person  and  any  person  with  respect  to  any
securities of the issuer, including but not limited to transfer or voting of any
of the securities,  finder's fees, joint ventures,  loan or option  arrangements
puts or calls, guarantees of profits, division of profits or loss, or the giving
or  withholding  of  proxies,  naming  the , persons  with whom such  contracts,
arrangements understandin or relationship have been entered into.



Item 7. Material to Be Filed as Exhibits

None.



                                                                               4



                                    Signature

After  reasonable  inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.

--------------------------------------------------------------------------------



Date: November 10, 2007


By:   /s/ Jian Yang
      -------------
        Jian Yang